NasdaqGM:FOLD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Amicus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FOLD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.1%

FOLD

0.2%

US Biotechs

2.8%

US Market


1 Year Return

4.4%

FOLD

25.7%

US Biotechs

9.3%

US Market

Return vs Industry: FOLD underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: FOLD underperformed the US Market which returned 9.3% over the past year.


Shareholder returns

FOLDIndustryMarket
7 Day4.1%0.2%2.8%
30 Day12.2%9.1%8.9%
90 Day31.0%11.9%-0.5%
1 Year4.4%4.4%26.9%25.7%11.8%9.3%
3 Year49.0%49.0%34.8%30.3%31.4%22.7%
5 Year-3.1%-3.1%-2.5%-8.3%58.7%40.9%

Price Volatility Vs. Market

How volatile is Amicus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amicus Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FOLD ($12.68) is trading below our estimate of fair value ($55.08)

Significantly Below Fair Value: FOLD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FOLD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FOLD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FOLD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FOLD is overvalued based on its PB Ratio (8.1x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

59.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FOLD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FOLD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FOLD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FOLD's revenue (36.5% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: FOLD's revenue (36.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FOLD is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Amicus Therapeutics performed over the past 5 years?

-26.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FOLD is currently unprofitable.

Growing Profit Margin: FOLD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FOLD is unprofitable, and losses have increased over the past 5 years at a rate of -26% per year.

Accelerating Growth: Unable to compare FOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: FOLD has a negative Return on Equity (-80.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Amicus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FOLD's short term assets ($407.9M) exceed its short term liabilities ($91.7M).

Long Term Liabilities: FOLD's short term assets ($407.9M) exceed its long term liabilities ($244.0M).


Debt to Equity History and Analysis

Debt Level: FOLD's debt to equity ratio (37.2%) is considered satisfactory.

Reducing Debt: FOLD's debt to equity ratio has increased from 12.9% to 37.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FOLD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FOLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FOLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FOLD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FOLD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FOLD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

John Crowley (52yo)

8.83yrs

Tenure

US$9,852,663

Compensation

Mr. John F. Crowley has been the Chairman of Amicus Therapeutics, Inc. since February 2010 and has been its Chief Executive Officer since August 15, 2011. Mr. Crowley served as the Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD9.85M) is above average for companies of similar size in the US market ($USD5.87M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Crowley
Chairman & CEO8.83yrsUS$9.85m0.39% $12.7m
Bradley Campbell
President2yrsUS$4.14m0.14% $4.5m
Daphne Quimi
Chief Financial Officer1.42yrsUS$2.48m0.029% $931.8k
Hung Do
Chief Scientific Officer4.92yrsUS$2.61m0.14% $4.5m
Ellen Rosenberg
Chief Legal Officer4.33yrsUS$2.69m0.020% $640.4k
Samantha Prout
Vice President of Finance2yrsno data0.0022% $73.5k
Enrique Diloné
Senior Vice President of Technical Operationsno datano datano data
Patrik Florencio
Senior VP4.83yrsno datano data
Mark Baldry
Senior Vice President of Global Marketing & Commercial Operations5yrsno datano data
Michael Diem
Senior Vice President of Business & Corporate Development2.75yrsno datano data

4.8yrs

Average Tenure

51.5yo

Average Age

Experienced Management: FOLD's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Crowley
Chairman & CEO8.83yrsUS$9.85m0.39% $12.7m
Bradley Campbell
President2yrsUS$4.14m0.14% $4.5m
Robert Essner
Independent Director8yrsUS$278.83k0.0034% $112.7k
Burke Whitman
Independent Director1yrUS$433.25kno data
Glenn Sblendorio
Independent Director14yrsUS$298.82k0.0073% $237.9k
Margaret McGlynn
Independent Director10.67yrsUS$296.33k0.0073% $239.5k
Ted Love
Independent Director8yrsUS$287.99k0.059% $1.9m
Craig Wheeler
Independent Director4yrsUS$284.67k0.0034% $112.7k
Michael Raab
Lead Independent Director1.75yrsUS$321.33k0.0034% $112.7k
Lynn Bleil
Independent Director1.75yrsUS$285.80k0.0015% $48.0k

6.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: FOLD's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

Amicus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amicus Therapeutics, Inc.
  • Ticker: FOLD
  • Exchange: NasdaqGM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.267b
  • Shares outstanding: 257.66m
  • Website: https://www.amicusrx.com

Number of Employees


Location

  • Amicus Therapeutics, Inc.
  • 1 Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FOLDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2007
AM6DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2007
0HF9LSE (London Stock Exchange)YesCommon StockGBUSDMay 2007
FOLD *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2007

Biography

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 03:23
End of Day Share Price2020/06/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.